Corporate Board Profile
Tech Score: 20/100
1 mention(s) identify JOSEPH TRUITT as having software/technology expertise.
| Company | Filing Date | Evidence | Reason |
|---|---|---|---|
| Larimar Therapeutics, Inc. | 2021-04-14 | Mr. Truitt currently serves as the Chief Executive Officer of Iecure Inc., a gene editing company, and is on the Board of CodeBio, a gene therapy development company. | Mr. Truitt is currently CEO of a gene editing company and on the board of a gene therapy development company, indicating involvement in advanced biotech technologies which often require software expertise. However, the filing does not explicitly state programming skills, but his leadership in gene editing and biotech companies suggests relevant technical background. |
| Filing Date | Source Excerpt |
|---|---|
| 2020-08-19 | Joseph Truitt 0 * |
| 2021-04-14 | Mr. Truitt currently serves as the Chief Executive Officer of Iecure Inc., a gene editing company, and is on the Board of CodeBio, a gene therapy development company. |
| 2022-04-12 | Mr. Truitt has a B.S. in Marketing and an M.B.A. in Pharmaceutical Marketing, with no mention of software or technical programming skills. |
| 2023-04-11 | Mr. Truitt currently serves as the Chief Executive Officer of iECURE, Inc., a gene editing company, and has held various executive roles in biopharmaceutical companies. He holds a B.S. in Marketing and an MBA. |
| 2024-04-29 | Mr. Truitt received his B.S. in Marketing from LaSalle University and his MBA from St. Joseph’s University in Pharmaceutical Marketing. |
Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-03-19